GLP-1 use displaces £1bn in British grocery spending

GLP-1 use displaces £1bn in British grocery spending

Worldpanel estimates weight-loss drugs are changing British grocery purchasing patterns. Households with GLP-1 users bought fewer products than comparable households, with annual displaced spending estimated at more than £1bn.


IN Brief:

  • Worldpanel estimates GLP-1 use has displaced more than £1bn in annual grocery spending, equivalent to £389 per household containing a user.
  • The proportion of British households with a user rose from 6.3% in February to 8.5% in August, based on a 9,629-household research sample.
  • The study found reduced purchases of alcohol and crisps but higher frozen ready meal volumes among GLP-1 user households.

Worldpanel by Numerator estimates that use of GLP-1 weight-loss medication has displaced more than £1 billion in annual grocery spending across Great Britain, as a growing proportion of households buy fewer food and drink products after treatment begins.

The research, published on 19 November, found that 8.5% of British households contained a GLP-1 user in August 2026, up from 6.3% in February. Worldpanel estimates that approximately 2.6 million adults were using the medications by August, an increase of about 700,000 over six months.

The firm’s analysis draws on the purchasing behaviour of 9,629 households. It compares households containing a user with similar households without one, estimating that grocery expenditure was £389 lower over a year after treatment began than would otherwise have been expected. Applied across the relevant population, the difference exceeds £1 billion and corresponds to approximately 415 million fewer packs bought.

That total is a modelled displacement relative to a comparison group, rather than a recorded fall of £1 billion in overall supermarket turnover. A change in one set of households’ shopping habits can coincide with growth among other consumers or in different product categories, and the retail value cannot be treated as an equivalent decline in food manufacturers’ receipts.

The estimate has increased from £780 million reported in June, reflecting a larger population of users despite the average annual displacement being £389 per affected household. Uptake has expanded both through conventional injectable treatments and through recently approved tablet formats.

According to the research, pills accounted for 11.2% of GLP-1 users in August, following UK regulatory approval during June. Men represented 32% of users, compared with 23% in February, with their estimated number rising from 440,000 to 830,000 over the six-month period.

The data do not establish that every user will make identical changes to food purchases. GLP-1 medications are associated with changes in appetite and eating patterns, but shopping behaviour is also affected by household composition, income, prices, personal preferences, and whether other people share the same food.

Category-level results are therefore more useful for production planning than the aggregate spending estimate alone. Worldpanel found that expenditure on alcohol and crisps fell about 15% more among households with users than among the comparison group. At the same time, volume sales of frozen ready meals rose 30% among user households.

That divergence suggests purchasing is being reallocated as well as reduced. The frozen meal finding is specific to households containing GLP-1 users; it does not establish a 30% increase across the entire British frozen ready meal market or prove that medication use alone caused the change.

Product manufacturers respond to shifts in demand through production scheduling, ingredient procurement, inventory management, and decisions about which formats to prioritise. Lower volumes for a particular snack can reduce the amount needed from established lines, while increased interest in other products may require different preparation, filling, and packaging capacity.

The effects can be particularly difficult to interpret where spending changes without a corresponding movement in units. A smaller pack may cost less but involve comparable handling and packaging activity, while a shift to a more expensive product could lift value even when the quantity purchased declines. For this reason, changes in consumer expenditure must be considered alongside unit and weight-based sales.

In frozen prepared foods, a sustained change in pack format could affect portioning, tray selection, filling weights, sealing equipment, and freezer capacity. These are potential manufacturing consequences rather than factory investments already documented by Worldpanel. The November research does not identify specific processors that have changed lines in response.

Reformulation is another possible response where consumers seek meals with a different balance of protein, fibre, energy, or portion size. Altering those characteristics can change viscosity, texture, moisture retention, heating behaviour, and the performance of ingredients during mixing, cooking, and packaging.

A change in the nutrient profile of a product is not automatically compatible with existing processing settings. Increasing protein content may require adjustments to ingredient hydration or heat treatment, while reducing portion weights can alter filling accuracy requirements and the ratio of packaging material to food delivered.

Manufacturers may also need to distinguish changes that last throughout treatment from short periods of altered buying behaviour. The data describe households after adoption, but do not provide a forecast of how long each individual will use the medication or what happens to purchasing patterns after treatment stops.

Worldpanel expects GLP-1 use to extend beyond 10% of British households in 2027. That is a projection rather than an observed adoption rate, and future penetration will depend on access to treatment, pricing, prescribing decisions, patient preferences, and the range of authorised formulations.

The study also indicates that spending does not simply disappear from the household budget. Separate reporting of Worldpanel’s findings identifies higher expenditure on health and beauty products among users, illustrating how money previously directed towards groceries may be allocated elsewhere.

Such redistribution means the £1 billion estimate should not be read as an industry-wide revenue forecast. Retailers, foodservice operators, and food manufacturers occupy different positions in the value chain, while the quantities purchased can move differently from selling prices and ingredient demand.

At a national level, most households still do not contain a GLP-1 user. Grocery prices, promotions, wider dietary preferences, and economic conditions continue to shape the production volumes required by the broader market. The research establishes an increasingly visible group of purchasers, not a replacement for established demand forecasting.

Subsequent category data will be needed to determine whether the changes observed in crisps, alcohol, and frozen ready meals persist as treatment use grows. Consistent measurements of packs, product weights, and category sales will provide food producers with a firmer basis for assessing whether shifts in consumption require altered recipes, production capacity, or packaging formats.


Stories for you


  • GLP-1 use displaces £1bn in British grocery spending

    GLP-1 use displaces £1bn in British grocery spending

    Worldpanel estimates weight-loss drugs are changing British grocery purchasing patterns. Households with GLP-1 users bought fewer products than comparable households, with annual displaced spending estimated at more than £1bn.


  • APM launches AP500 sack filler for food ingredients

    APM launches AP500 sack filler for food ingredients

    APM has introduced an auger-fed sack filler for food ingredients. The UK-built AP500 weighs products directly into open-mouth bags and can be integrated with automatic bag placement, sealing, and palletising equipment.